Browsing by Author "Hamm, Bernd"

Now showing 1 - 8 of 8
  • No Thumbnail Available
    Item
    ADAMTS4-specific MR probe to assess aortic aneurysms in vivo using synthetic peptide libraries
    (2022) Kaufmann, Jan O.; Brangsch, Julia; Kader, Avan; Saatz, Jessica; Mangarova, Dilyana B.; Zacharias, Martin; Kempf, Wolfgang E.; Schwaar, Timm; Ponader, Marco; Adams, Lisa C.; Moeckel, Jana; Botnar, Rene M.; Taupitz, Matthias; Maegdefessel, Lars; Traub, Heike; Hamm, Bernd; Weller, Michael G.; Makowski, Marcus R.
    New biomarkers are required to improve the assessment of aortic wall integrity and risk of rupture. Here the authors report the development of an imaging probe for ADAMTS4, which they test in an abdominal aortic aneurysm mouse model and show in vivo prediction of aneurysm and rupture.
  • Thumbnail Image
    Item
    Assessment of Albumin ECM Accumulation and Inflammation as Novel In Vivo Diagnostic Targets for Multi-Target MR Imaging
    (2021) Möckel, Jana; Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan O.; Sack, Ingolf; Mangarova, Dilyana B.; Avan, Kader; Taupitz, Matthias; Adams, Lisa C.; Keller, Sarah; Antje, Ludwig; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
  • No Thumbnail Available
    Item
    Concurrent Molecular Magnetic Resonance Imaging of Inflammatory Activity and Extracellular Matrix Degradation for the Prediction of Aneurysm Rupture
    (2019) Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan O.; Adams, Lisa C.; Onthank, David C.; Thone-Reineke, Christa; Robinson, Simon P.; Buchholz, Rebecca; Karst, Uwe; Botnar, Rene M.; Hamm, Bernd; Makowski, Marcus R.
    BACKGROUND: Molecular magnetic resonance imaging is a promising modality for the characterization of abdominal aortic aneurysms (AAAs). The combination of different molecular imaging biomarkers may improve the assessment of the risk of rupture. This study investigates the feasibility of imaging inflammatory activity and extracellular matrix degradation by concurrent dual-probe molecular magnetic resonance imaging in an AAA mouse model.
  • Thumbnail Image
    Item
    Dual-probe molecular MRI for the in vivo characterization of atherosclerosis in a mouse model : Simultaneous assessment of plaque inflammation and extracellular-matrix remodeling
    (2019) Reimann, Carolin; Brangsch, Julia; Kaufmann, Jan Ole; Adams,Lisa C.; Onthank, David C.; Thöne Reineke, Christa; Robinson, Simon P.; Hamm, Bernd; Botnar, René Michael; Makowski, Marcus R.
  • No Thumbnail Available
    Item
    Elastin-specific MR probe for visualization and evaluation of an interleukin-1β targeted therapy for atherosclerosis
    (2024) Mangarova, Dilyana Branimirova; Reimann, Carolin; Kaufmann, Jan Ole; Moeckel, Jana; Kader, Avan; Adams, Lisa Christine; Ludwig, Antje; Onthank, David; Robinson, Simon; Karst, Uwe; Helmer, Rebecca; Botnar, Rene; Hamm, Bernd; Makowski, Marcus Richard; Brangsch, Julia
    Atherosclerosis is a chronic inflammatory condition of the arteries and represents the primary cause of various cardiovascular diseases. Despite ongoing progress, finding effective anti-inflammatory therapeutic strategies for atherosclerosis remains a challenge. Here, we assessed the potential of molecular magnetic resonance imaging (MRI) to visualize the effects of 01BSUR, an anti-interleukin-1 beta monoclonal antibody, for treating atherosclerosis in a murine model. Male apolipoprotein E-deficient mice were divided into a therapy group (01BSUR, 2 x 0.3 mg/kg subcutaneously, n = 10) and control group (no treatment, n = 10) and received a high-fat diet for eight weeks. The plaque burden was assessed using an elastin-targeted gadolinium-based contrast probe (0.2 mmol/kg intravenously) on a 3 T MRI scanner. T1-weighted imaging showed a significantly lower contrast-to-noise (CNR) ratio in the 01BSUR group (pre: 3.93042664; post: 8.4007067) compared to the control group (pre: 3.70679168; post: 13.2982156) following administration of the elastin-specific MRI probe (p < 0.05). Histological examinations demonstrated a significant reduction in plaque size (p < 0.05) and a significant decrease in plaque elastin content (p < 0.05) in the treatment group compared to control animals. This study demonstrated that 01BSUR hinders the progression of atherosclerosis in a mouse model. Using an elastin-targeted MRI probe, we could quantify these therapeutic effects in MRI.
  • Thumbnail Image
    Item
    Molecular MR-Imaging for Noninvasive Quantification of the Anti-Inflammatory Effect of Targeting Interleukin-1β in a Mouse Model of Aortic Aneurysm
    (SAGE Publications Inc., 2020) Brangsch, Julia; Reimann, Carolin; Kaufmann, Jan Ole; Adams, Lisa Christine; Hamm, Bernd; Makowski, Marcus Richard; Thöne-Reineke, Christa; Wilke, Marco; Weller, Michael; Onthank, David; Robinson, Simon; Buchholz, Rebecca; Karst, Uwe; Botnar, Rene Michael
    Molecular-MRI is a promising imaging modality for the assessment of abdominal aortic aneurysms (AAAs). Interleukin-1β (IL-1β) represents a new therapeutic tool for AAA-treatment, since pro-inflammatory cytokines are key-mediators of inflammation. This study investigates the potential of molecular-MRI to evaluate therapeutic effects of an anti-IL-1β-therapy on AAA-formation in a mouse-model. Methods: Osmotic-minipumps were implanted in apolipoprotein-deficient-mice (N = 27). One group (Ang-II+01BSUR group, n = 9) was infused with angiotensin-II (Ang-II) for 4 weeks and received an anti-murine IL-1β-antibody (01BSUR) 3 times. One group (Ang-II-group, n = 9) was infused with Ang-II for 4 weeks but received no treatment. Control-group (n = 9) was infused with saline and received no treatment. MR-imaging was performed using an elastin-specific gadolinium-based-probe (0.2 mmol/kg). Results: Mice of the Ang-II+01BSUR-group showed a lower aortic-diameter compared to mice of the Ang-II-group and control mice (p < 0.05). Using the elastin-specific-probe, a significant decrease in elastin-destruction was observed in mice of the Ang-II+01BSUR-group. In vivo MR-measurements correlated well with histopathology (y = 0.34x-13.81, R2 = 0.84, p < 0.05), ICP-MS (y = 0.02x+2.39; R2 = 0.81, p < 0.05) and LA-ICP-MS. Immunofluorescence and western-blotting confirmed a reduced IL-1β-expression. Conclusions: Molecular-MRI enables the early visualization and quantification of the anti-inflammatory-effects of an IL-1β-inhibitor in a mouse-model of AAAs. Responders and non-responders could be identified early after the initiation of the therapy using molecular-MRI.
  • Thumbnail Image
    Item
    Noninvasive Imaging of Endothelial Damage in Patients With Different HbA(1c) Levels : A Proof-of-Concept Study
    (2019) Engel, Leif-Christopher; Landmesser, Ulf; Goehler, Alexander; Gigengack, Kevin; Wurster, Thomas-Heinrich; Manes, Costantina; Girke, Georg; Jaguszewski, Milosz; Skurk, Carsten; Botnar, René Michael; Leistner, David M.; Lauten, Alexander; Schuster, Andreas; Noutsias, Michel; Hamm, Bernd; Bigalke, Boris; Makowski, Marcus R.
  • Thumbnail Image
    Item
    Simultaneous [18F]fluoride and gadobutrol enhanced coronary positron emission tomography/magnetic resonance imaging for in vivo plaque characterization
    (Oxford University Press, 2022) Wurster, Thomas H.; Landmesser, Ulf; Abdelwahed, Youssef S.; Skurk, Carsten; Morguet, Andreas; Leistner, David M.; Froehlich, Georg; Haghikia, Arash; Engel, Leif Christopher; Botnar, René Michael; Schuster, Andreas; Noutsias, Michel; Schulze, Daniel; Hamm, Bernd; Furth, Christian; Brenner, Winfried; Bigalke, Boris; Makowski, Marcus R.
    Aims F-18-sodium fluoride ([18F]fluoride) and gadobutrol are promising probes for positron emission tomography (PET) and magnetic resonance imaging (MRI) characterizing coronary artery disease (CAD) activity. Unlike [18F]fluoride-PET/computed tomography (CT), the potential of PET/MR using [18F]fluoride and gadobutrol simultaneously, has so far not been evaluated. This study assessed feasibility and diagnostic potential of [18F]fluoride and gadobutrol enhanced dual-probe PET/MR in patients with CAD. Methods and results Twenty-one patients (age, 66.7 +/- 6.7 years) with CAD scheduled for invasive coronary angiography (XCA) underwent simultaneous [18F]fluoride (mean activity/effective dose: 157.2 +/- 29.7 MBq/3.77 +/- 0.72 mSv) and gadobutrol enhanced PET/MR on an integrated PET/MRI (3 T) scanner. Optical coherence tomography (OCT) was used as reference. Target-to-background ratio (TBR, [18F]fluoride-PET) and contrast-to-noise ratio (CNR) values (MRI, gadobutrol) were calculated for each coronary segment. Previously suggested PET/CT-TBR thresholds for adverse coronary events were evaluated. High-risk plaques, i.e. calcified and non-calcified thin-cap fibroatheromas (TCFAs) were predominantly located in segments with a TBR >1.28 (P = 0.012). Plaques containing a lipid core on OCT, were more frequently detected in segments with a TBR >1.25 (P < 0.001). TBR values significantly correlated with maximum calcification thickness (P = 0.009), while fibrous cap thickness was significantly less in segments with a TBR >1.28 (P = 0.044). Above a TBR threshold of >1.28, CNR values significantly correlated with the presence of calcified TCFAs (P = 0.032). Conclusion Simultaneous [18F]fluoride and gadobutrol dual-probe PET/MRI is feasible in clinical practice and may facilitate the identification of high-risk patients. The combination of coronary MR-derived CNR values post gadobutrol and [18F]fluoride based TBR values may improve identification of high-risk plaque features.